Royce & Associates LP Sells 179,580 Shares of Harrow, Inc. (NASDAQ:HROW)

Royce & Associates LP reduced its position in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 33.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 360,320 shares of the company's stock after selling 179,580 shares during the quarter. Royce & Associates LP owned about 1.02% of Harrow worth $16,200,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Huntington National Bank bought a new stake in shares of Harrow during the third quarter worth approximately $164,000. Oppenheimer & Co. Inc. acquired a new stake in Harrow during the 3rd quarter worth $1,267,000. Corrado Advisors LLC acquired a new stake in Harrow during the 3rd quarter worth $331,000. Principal Financial Group Inc. bought a new stake in shares of Harrow during the 3rd quarter valued at $329,000. Finally, Hills Bank & Trust Co acquired a new position in shares of Harrow in the 3rd quarter valued at $107,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on HROW. B. Riley reaffirmed a "buy" rating and set a $50.00 price objective on shares of Harrow in a research note on Thursday, August 29th. Craig Hallum boosted their target price on Harrow from $45.00 to $65.00 and gave the stock a "buy" rating in a research report on Friday, October 4th. Finally, Lake Street Capital upped their price target on Harrow from $45.00 to $55.00 and gave the company a "buy" rating in a research note on Friday, October 4th.

Harrow Trading Down 9.0 %

Shares of HROW traded down $3.85 during trading hours on Friday, reaching $39.01. The stock had a trading volume of 1,347,541 shares, compared to its average volume of 511,814. The firm has a 50-day moving average of $47.92 and a 200 day moving average of $32.43. The company has a quick ratio of 2.43, a current ratio of 2.60 and a debt-to-equity ratio of 3.18. The company has a market cap of $1.38 billion, a P/E ratio of -41.50 and a beta of 0.76. Harrow, Inc. has a 52 week low of $8.01 and a 52 week high of $59.23.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.